<DOC>
	<DOCNO>NCT00433784</DOCNO>
	<brief_summary>The purpose study ass whether interpatient variability platelet response clopidogrel partly due polymorphism hepatic cytochrome P450 ( CYP450 ) 3A clopidogrel-P2Y12 receptor gene .</brief_summary>
	<brief_title>H2 Haplotype CYP3As Polymorphisms Antiplatelet Response Clopidogrel</brief_title>
	<detailed_description>Clopidogrel owe antiplatelet effect irreversible inhibition purinergic platelet receptor , P2Y12 . It estimate approximately 4 % -30 % patient treat conventional dos clopidogrel display adequate platelet response . Moreover , patient low response clopidogrel may higher risk atherothrombotic event . Clopidogrel , prodrug , require oxidation hepatic cytochrome P450 ( CYP450 ) 3A generate active metabolite.The level CYP3A4 activity show correlate inhibitory effect clopidogrel platelet aggregation healthy volunteer . However , CYP3As expression activity vary among individual . It estimate variability cause individual genetic makeup.Polymorphisms P2Y12 receptor may also play role variability clopidogrel response . The P2Y12-H2 haplotype associate high maximal platelet aggregation response adenosine diphosphate ( ADP ) compare P2Y12-H1 haplotype probably due increase number receptor platelet surface . It also suggest carrier H2 haplotype might high risk develop peripheral artery disease . Comparisons : Presence CYP3A5 polymorphism H2 haplotype compare absence polymorphism antiplatelet response clopidogrel across wide range clopidogrel dose regimen patient suspect demonstrated coronary artery disease ( CAD ) schedule undergo elective percutaneous coronary intervention ( PCI ) . Platelet aggregation measure optical aggregometry ( ADP ) 20 Î¼mol/L agonist patient clopidogrel initiation time diagnostic coronary angiography . Genotyping performed standard polymerase chain reaction ( PCR ) method identify expressors CYP3A5 P2Y12 H2 haplotype carrier .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Documented coronary artery disease ( CAD ) require elective diagnostic coronary angiography without percutaneous coronary intervention ( PCI ) Major bleed disorder active bleeding ; Acute MI within 14 day recruitment ; Unstable angina STsegment change &gt; = 1 mm least two contiguous electrocardiographic lead rest , troponin level &gt; 0.06 ug/L within 14 day recruitment ; Stroke within last 3 month ; Platelet count &lt; 100 x 109/L ; Prothrombin time &gt; 1.5 time control ; Hematocrit &lt; 25 % hemoglobin level &lt; 100 g/L ; Alcohol drug abuse ; Enrolment investigational drug trial within previous month ; Use thienopyridines , glycoprotein ( GP ) IIb/IIIa inhibitor , warfarin acenocoumarol within prior week ; Allergic reaction contraindication clopidogrel aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>platelet aggregation</keyword>
	<keyword>CYP3A</keyword>
	<keyword>H2 haplotype</keyword>
	<keyword>polymorphism</keyword>
</DOC>